On February 6, FDA announced its intention to take decisive enforcement action against non-FDA-approved compounded GLP-1 drugs, specifically identifying restrictions on GLP-1 active pharmaceutical ingredients (APIs) used in mass-marketed compounded products
Journal of Strength and Conditioning Research, 21(1), 259
If you or a family member has experienced serious complications after taking a GLP-1 drug such as Ozempic, Wegovy, Mounjaro, or Zepbound, our Chicago product liability lawyers are here to help
Flow Wellness provides medical weight-loss consultations and GLP-1 treatment programs through telehealth for eligible patients in Oregon, Washington, and California, with in-person care available at our Bend and Seattle clinics